lumacaftor · Orkambi
Small molecule
Evidence outlook
Approved: Cystic Fibrosis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (2)
- ORKAMBI (lumacaftor/ivacaftor) is indicated for the treatment of cystic fibrosis (CF) in patients 1 year of age and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Limitations of Use The efficacy and safety of ORKAMBI have not been established in patients with CF other than those homozygous for the F508del mutation.
- Cystic fibrosis in patients homozygous for the F508del mutation in the CFTR gene (Orkambi, lumacaftor/ivacaftor; MAH Vertex Pharmaceuticals (Ireland) Limited)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
TRANSPORT NCT01807949 · Cystic Fibrosis, Homozygous for the F508del CFTR Mutation The trial was randomized, double-blind, placebo-controlled, and included 563 participants. The hard clinical primary endpoint, change in percent-predicted FEV1, was significantly better with both lumacaftor/ivacaftor regimens than placebo: the treatment differences were 2.62 percentage points (p=0.0004) and 3.00 percentage points (p<0.0001). Registry: NCT01807949 | 3 | Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 24 (Baseline, Week 16 and 24) 2014-04 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
View 1 more trial
TRAFFIC NCT01807923 · Cystic Fibrosis, Homozygous for the F508del CFTR Mutation This was a randomized, double-blind, placebo-controlled trial with 559 participants and a clinically meaningful primary lung-function endpoint. The primary endpoint was met for both lumacaftor/ivacaftor regimens, with statistically significant improvements in percent-predicted FEV1 versus placebo. Registry: NCT01807923 | 3 | Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 24 (Baseline, Week 16 and 24) 2014-04 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Early phase / not applicable (3)
What this study did
What this study did
What this study did
Competitive landscape
5 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Cystic Fibrosis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Lumacaftor (Orkambi): this drug | Approved | Small molecule | CFTR | Reliable signal | No reviewed efficacy summary in this indication | |
| Elexacaftor / Tezacaftor / Ivacaftor (Trikafta) | Approved | Small molecule | CFTR, CFTR | Reliable signal | NCT03525444: Absolute change in ppFEV1 from baseline at Week 4 (interim analysis, 403 patients): treatment difference vs placebo 13.8 percentage points (95% CI 12.1 to 15.4), P<0.0001; CT.gov LS means +13.6 vs -0.2 (TRIKAFTA label section 14.1; CT.gov posted results). NCT03525548: Absolute change in ppFEV1 from baseline at Week 4 vs tezacaftor/ivacaftor: +10.4 vs +0.4; treatment difference 10.0 percentage points (95% CI 7.4 to 12.6), P<0.0001 (TRIKAFTA label section 14.1; CT.gov posted results). | |
| Ivacaftor (Kalydeco) | Approved | Small molecule | CFTR | Partial signal | NCT00909727: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo 0.1 percent of predicted volume (L) (Standard Error 2.1) | 150 mg Ivacaftor q12h 12.6 percent of predicted volume (L) (Standard Error 2.1) NCT00909532: Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo -0.2 percent of predicted volume (L) (Standard Error 0.7) | 150 mg Ivacaftor q12h 10.4 percent of predicted volume (L) (Standard Error 0.7) | |
| Tezacaftor / Ivacaftor (Symdeko) | Approved | Small molecule | CFTR | not yet graded | No reviewed efficacy summary in this indication | |
| Vanzacaftor / Tezacaftor / Deutivacaftor (Alyftrek) | Approved | Small molecule | CFTR, CFTR | Reliable signal | No reviewed efficacy summary in this indication | |
| KB407 | Phase 1 | Gene therapy / editing | CFTR (gene replacement) | not yet graded | No reviewed efficacy summary in this indication | |
| VX-828 | Phase 1 | Small molecule | CFTR | not yet graded | No reviewed efficacy summary in this indication | |
| Luvomeran | Discontinued | RNA / oligonucleotide | CFTR (mRNA replacement) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.